Released Mar 31, 2022, after the close
10-K filed Mar 31, 2022, 90 days after period end · 0000950170-22-005194
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$29.30M-$29.30M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$27,502,000N/M
Operating Cash Flowderived-$27,349,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $696.00K | $1.69M |
| Net Income | -$29.30M | -$18.60M | -$24.99M | -$10.60M |
| EPS Diluted | — | — | -$1.31 | -$0.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR